MedTrace Logo

Evidence of Haloperidol Absorption After Topical Administration

NCT01684969 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2016-03-17

No results posted yet for this study

Summary

This will be a blinded study to compare the absorption of topical haloperidol with placebo

Conditions

Interventions

DRUG

Haloperidol

0.5 mg iv x one dose

DRUG

Placebo

0.5 mg iv , one dose

Sponsors & Collaborators

  • Eric E. Prommer

    lead OTHER

Principal Investigators

  • Eric Prommer, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2013-05-31
Completion
2013-05-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01684969 on ClinicalTrials.gov